{"id":48939,"date":"2025-11-25T16:27:19","date_gmt":"2025-11-25T08:27:19","guid":{"rendered":"https:\/\/flcube.com\/?p=48939"},"modified":"2025-11-25T16:27:20","modified_gmt":"2025-11-25T08:27:20","slug":"cstones-sugemalimab-wins-eu-approval-for-stage-iii-nsclc-expanding-european-indication","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48939","title":{"rendered":"CStone&#8217;s Sugemalimab Wins EU Approval for Stage III NSCLC, Expanding European Indication"},"content":{"rendered":"\n<p><strong>CStone Pharmaceuticals<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2616:HKG\">HKG: 2616<\/a>) announced that the <strong>European Commission (EC)<\/strong> has approved a new indication for <strong>sugemalimab<\/strong> as monotherapy for adult patients with <strong>unresectable Stage III non\u2011small cell lung cancer (NSCLC)<\/strong> following platinum\u2011based chemoradiotherapy, marking the second EU approval that covers the full NSCLC spectrum from locally advanced to metastatic disease.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Sugemalimab (anti\u2011PD\u2011L1 monoclonal antibody)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>CStone Pharmaceuticals (HKEX: 2616)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>European Commission (EC)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>New indication (monotherapy)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Unresectable Stage III NSCLC, PD\u2011L1\u202f\u2265\u202f1%, no EGFR\/ALK\/ROS1 mutations, post platinum\u2011based CRT<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td>Second EU approval; covers full NSCLC spectrum from Stage III to Stage IV<\/td><\/tr><tr><td><strong>Previous Approval<\/strong><\/td><td>First\u2011line metastatic NSCLC in combination with chemotherapy (approved by EC and MHRA)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Anti\u2011PD\u2011L1 monoclonal antibody that restores T\u2011cell mediated anti\u2011tumor immunity<\/li>\n\n\n\n<li><strong>Clinical Differentiation:<\/strong> Now the <strong>only PD\u2011L1 inhibitor<\/strong> approved across both <strong>Stage III (post\u2011CRT)<\/strong> and <strong>Stage IV (first\u2011line)<\/strong> NSCLC settings in Europe<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Expands addressable patient population by <strong>~35%<\/strong> in EU markets<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence\">Clinical Evidence<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Approval Basis:<\/strong> Clinical data package demonstrating efficacy and safety in Stage III NSCLC patients meeting specified criteria<\/li>\n\n\n\n<li><strong>Target Population:<\/strong> Approximately <strong>15\u201120%<\/strong> of newly diagnosed NSCLC patients present with unresectable Stage III disease in Europe<\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> Consistent with approved PD\u2011L1 inhibitor class; no new safety signals identified<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>EU Market Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Stage III NSCLC Incidence<\/strong><\/td><td>~45,000 patients annually<\/td><\/tr><tr><td><strong>Current Standard<\/strong><\/td><td>AstraZeneca\u2019s Imfinzi (durvalumab) dominates post\u2011CRT consolidation<\/td><\/tr><tr><td><strong>Peak Sales Forecast (Sugemalimab)<\/strong><\/td><td><strong>\u20ac400\u2011550\u202fmillion<\/strong> by 2030 (assuming 25\u201130% market share)<\/td><\/tr><tr><td><strong>Competitive Edge:<\/strong> Single agent covering both Stage III and Stage IV may simplify treatment pathways and hospital formularies<\/td><td><\/td><\/tr><tr><td><strong>Next Catalyst:<\/strong> Phase\u202fIII data presentation at major oncology conference <strong>Q1\u202f2026<\/strong><\/td><td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding sugemalimab\u2019s commercial potential, market penetration, and competitive position in Europe. Actual results may differ materially due to risks including physician adoption rates, reimbursement negotiations, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CStone Pharmaceuticals (HKG: 2616) announced that the European Commission (EC) has approved a new indication&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48940,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[188,856,15],"class_list":["post-48939","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cstone-pharmaceuticals","tag-hkg-2616","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CStone&#039;s Sugemalimab Wins EU Approval for Stage III NSCLC, Expanding European Indication - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CStone Pharmaceuticals (HKG: 2616) announced that the European Commission (EC) has approved a new indication for sugemalimab as monotherapy for adult patients with unresectable Stage III non\u2011small cell lung cancer (NSCLC) following platinum\u2011based chemoradiotherapy, marking the second EU approval that covers the full NSCLC spectrum from locally advanced to metastatic disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48939\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CStone&#039;s Sugemalimab Wins EU Approval for Stage III NSCLC, Expanding European Indication\" \/>\n<meta property=\"og:description\" content=\"CStone Pharmaceuticals (HKG: 2616) announced that the European Commission (EC) has approved a new indication for sugemalimab as monotherapy for adult patients with unresectable Stage III non\u2011small cell lung cancer (NSCLC) following platinum\u2011based chemoradiotherapy, marking the second EU approval that covers the full NSCLC spectrum from locally advanced to metastatic disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48939\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-25T08:27:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-25T08:27:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2501.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48939#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48939\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CStone&#8217;s Sugemalimab Wins EU Approval for Stage III NSCLC, Expanding European Indication\",\"datePublished\":\"2025-11-25T08:27:19+00:00\",\"dateModified\":\"2025-11-25T08:27:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48939\"},\"wordCount\":337,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48939#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2501.webp\",\"keywords\":[\"CStone Pharmaceuticals\",\"HKG: 2616\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48939#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48939\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48939\",\"name\":\"CStone's Sugemalimab Wins EU Approval for Stage III NSCLC, Expanding European Indication - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48939#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48939#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2501.webp\",\"datePublished\":\"2025-11-25T08:27:19+00:00\",\"dateModified\":\"2025-11-25T08:27:20+00:00\",\"description\":\"CStone Pharmaceuticals (HKG: 2616) announced that the European Commission (EC) has approved a new indication for sugemalimab as monotherapy for adult patients with unresectable Stage III non\u2011small cell lung cancer (NSCLC) following platinum\u2011based chemoradiotherapy, marking the second EU approval that covers the full NSCLC spectrum from locally advanced to metastatic disease.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48939#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48939\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48939#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2501.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2501.webp\",\"width\":1080,\"height\":608,\"caption\":\"CStone's Sugemalimab Wins EU Approval for Stage III NSCLC, Expanding European Indication\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48939#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CStone&#8217;s Sugemalimab Wins EU Approval for Stage III NSCLC, Expanding European Indication\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CStone's Sugemalimab Wins EU Approval for Stage III NSCLC, Expanding European Indication - Insight, China&#039;s Pharmaceutical Industry","description":"CStone Pharmaceuticals (HKG: 2616) announced that the European Commission (EC) has approved a new indication for sugemalimab as monotherapy for adult patients with unresectable Stage III non\u2011small cell lung cancer (NSCLC) following platinum\u2011based chemoradiotherapy, marking the second EU approval that covers the full NSCLC spectrum from locally advanced to metastatic disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48939","og_locale":"en_US","og_type":"article","og_title":"CStone's Sugemalimab Wins EU Approval for Stage III NSCLC, Expanding European Indication","og_description":"CStone Pharmaceuticals (HKG: 2616) announced that the European Commission (EC) has approved a new indication for sugemalimab as monotherapy for adult patients with unresectable Stage III non\u2011small cell lung cancer (NSCLC) following platinum\u2011based chemoradiotherapy, marking the second EU approval that covers the full NSCLC spectrum from locally advanced to metastatic disease.","og_url":"https:\/\/flcube.com\/?p=48939","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-25T08:27:19+00:00","article_modified_time":"2025-11-25T08:27:20+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2501.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48939#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48939"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CStone&#8217;s Sugemalimab Wins EU Approval for Stage III NSCLC, Expanding European Indication","datePublished":"2025-11-25T08:27:19+00:00","dateModified":"2025-11-25T08:27:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48939"},"wordCount":337,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48939#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2501.webp","keywords":["CStone Pharmaceuticals","HKG: 2616","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48939#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48939","url":"https:\/\/flcube.com\/?p=48939","name":"CStone's Sugemalimab Wins EU Approval for Stage III NSCLC, Expanding European Indication - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48939#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48939#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2501.webp","datePublished":"2025-11-25T08:27:19+00:00","dateModified":"2025-11-25T08:27:20+00:00","description":"CStone Pharmaceuticals (HKG: 2616) announced that the European Commission (EC) has approved a new indication for sugemalimab as monotherapy for adult patients with unresectable Stage III non\u2011small cell lung cancer (NSCLC) following platinum\u2011based chemoradiotherapy, marking the second EU approval that covers the full NSCLC spectrum from locally advanced to metastatic disease.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48939#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48939"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48939#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2501.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2501.webp","width":1080,"height":608,"caption":"CStone's Sugemalimab Wins EU Approval for Stage III NSCLC, Expanding European Indication"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48939#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CStone&#8217;s Sugemalimab Wins EU Approval for Stage III NSCLC, Expanding European Indication"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2501.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48939","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48939"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48939\/revisions"}],"predecessor-version":[{"id":48941,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48939\/revisions\/48941"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48940"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48939"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48939"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48939"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}